等待开盘 10-14 09:30:00 美东时间
+0.030
+0.07%
今日重点评级关注:摩根士丹利:维持TeraWulf"超配"评级,目标价从62.5美元升至65美元;摩根士丹利:维持Hut 8"超配"评级,目标价从273美元升至275美元
10-13 12:30
JP Morgan analyst Richard Shane downgrades Enact Holdings (NASDAQ:ACT) from Neutral to Underweight and lowers the price target from $48 to $44.
10-12 20:09
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.2% on Monday. Shares of Standard Motor Products Inc (NYSE:SMP) fell sharply in pre-market trading. Standard Motor Products named James J. Burke as interim CFO, effective Oct. 30, succeeding Nathan R. Iles. Standard Mot...
10-12 20:02
Enact Holdings (NASDAQ:ACT) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. The full earnings call ...
10-05 19:09
BofA Research has identified a group of Russell 2000 stocks rated Buy or Neutral that rank well on factors that have historically outperformed during periods of Federal Reserve interest-rate hikes. Th...
09-23 23:26
Enact Holdings, Inc. announced that A.M. Best upgraded the insurance financial strength rating for its subsidiaries to A from A- and its long-term issuer rating to BBB from BBB-. This marks Enact's first upgrade since A.M. Best initiated coverage in 2023, reflecting its strong performance and capital position. CEO Rohit Gupta expressed confidence in the company's ability to serve lenders and borrowers while generating value for shareholders. Enac...
09-18 20:15
Genworth Financial's (GNW) board authorized an additional $500M for the repurchase of the company's shares under its existing share repurchase program, the company said Wednesday. As of Sept. 1, 20...
09-03 04:28
Thomas J. McInerney will return from a leave of absence to resume his role as Genworth Financial's (GNW) president and CEO as of Sept. 2, 2026, the company said Thursday. As a result, Jerome T. Upton...
08-21 04:39
今日重点评级关注:HC Wainwright & Co.:维持Innate Pharma"买入"评级,目标价从5美元升至7美元;HC Wainwright & Co.:维持Immix Biopharma"买入"评级,目标价从20美元升至25美元
08-11 11:45
今日重点评级关注:康托·菲茨杰拉德:维持InflaRx"超配"评级,目标价从4美元升至6美元;RBC Capital:维持Nuvation Bio"跑赢大市"评级,目标价从19美元升至20美元
08-10 19:24